Back to Search
Start Over
Supplementary Table 1 from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Table 1 - PDF file 37K, Most Common (incidence >10%) Grade 3/4 Toxicities per Dose Group
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....04169764492612da2699f37c9fae8578
- Full Text :
- https://doi.org/10.1158/1078-0432.22445375.v1